C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) A61K 31/70 (2006.01) A61K 48/00 (2006.01) C07H 21/00 (2006.01) C07K 14/03 (2006.01) C12N 15/11 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2074523
2074523 9112811 PCTABS00007 Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42, and UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.
Crooke Stanley T.
Draper Kenneth G.
Ecker David J.
Mirabelli Christopher K.
Borden Ladner Gervais Llp
Isis Pharmaceuticals Inc.
LandOfFree
Oligonucleotide therapies for modulating the effects of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide therapies for modulating the effects of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide therapies for modulating the effects of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1816131